External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

Shanghai Henlius Biotech  / Equity Bottom-Up

<ul><li>Strong revenue growth and improved operating efficiency drive positive earnings.</li><li>Henlius’ 1H23 revenue increased 94% YoY to RMB2.50bn, mainly driven by the strong sales growth of HANQUYOU (trastuzumab biosimilar) and HANSIZHUANG (PD-1 mAb).</li><li>The GP margin (vs product sales) was 66.5% in 1H23 (vs 68.4% in FY22). </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Strong revenue growth and improved operating efficiency drive positive earnings.Henlius’ 1H23 revenue increased 94% YoY to RMB2.50bn, mainly driven by the strong sales growth of HANQUYOU (trastuzumab biosimilar) and HANSIZHUANG (PD-1 mAb).The GP margin (vs product sales) was 66.5% in 1H23 (vs 68.4% in FY22). Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Henlius Biotech (2696 HK) – Profit Turnaround in 1H23

China

Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Shanghai Henlius Biotech (2696 HK)

Henlius Biotech (2696 HK) – Profit Turnaround in 1H23

Henlius’ 1H23 revenue increased 94% YoY to RMB2.50bn, mainly driven by the strong sales growth of HANQUYOU (trastuzumab biosimilar) and HANSIZHUANG...

CMB International

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)